Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment

Schwarzbich Mark-Alexander; Schoening Tilman; Cremer Martin; Lisenko Katharina; Ho Anthony D.; Witzens-Harig Matthias

首页> 外文期刊>Leukemia and lymphoma >Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment

【24h】

Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment

机译：利妥昔单抗和甲氨蝶呤治疗方案（GMALL B-ALL / NHL 2002方案）作为一线治疗对高危弥漫性大细胞B细胞淋巴瘤患者的疗效和毒性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia and lymphoma》 |2016年第7期|共4页
作者
Schwarzbich Mark-Alexander; Schoening Tilman; Cremer Martin; Lisenko Katharina; Ho Anthony D.; Witzens-Harig Matthias;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment [J] . Schwarzbich Mark-Alexander, Schoening Tilman, Cremer Martin, Leukemia and lymphoma . 2016,第7期

机译：利妥昔单抗和甲氨蝶呤治疗方案（GMALL B-ALL / NHL 2002方案）作为一线治疗对高危弥漫性大细胞B细胞淋巴瘤患者的疗效和毒性
2. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentose Tumortherapie AGMT] (NHL-14) [J] . Fridrik Michael A., Jaeger Ulrich, Petzer Andreas, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：与利妥昔单抗，环磷酰胺，阿霉素，长春新碱和泼尼松龙相比，利妥昔单抗，环磷酰胺，非聚乙二醇脂质体阿霉素，长春新碱和泼尼松龙在前线治疗弥漫性大B细胞淋巴瘤患者中的心脏毒性来自奥地利癌症药物的一项随机III期研究治疗工作组[Arbeitsgemeinschaft Medikamentose肿瘤治疗AGMT]（NHL-14）
3. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: A population-based cohort study on treatment, toxicity and outcome [J] . BoslooperK., KibbelaarR., StormH., Leukemia and lymphoma . 2014,第3期

机译：利妥昔单抗，环磷酰胺，阿霉素，长春新碱和泼尼松龙治疗对老年弥漫性大B细胞淋巴瘤患者是有益的但有毒性：基于人群的治疗，毒性和预后队列研究
4. Clinical significance and expression of microRNA-21 in diffuse large B-cell lymphoma cell lines and serum of patients [C] . CHEN Wei-qun, LU Honf-da, KONG De-yong, 2011 Asia-Pacific Conference of tumor biology and medicine . 2011

机译：患者弥漫性大B细胞淋巴瘤细胞株和血清中microRNA-21的表达及临床意义
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkins lymphoma (B-NHL)--results of the UKCCSG 9003 protocol. [O] . A. Atra, M. Gerrard, R. Hobson, 1998

机译：B细胞急性淋巴细胞白血病（B-ALL）和IV期B细胞非霍奇金淋巴瘤（B-NHL）儿童的治愈率提高-UKCCSG 9003方案的结果。
7. Efficacy and Adverse Effects of Rituximab Combined with a TCOP Regimen in Patients with Untreated Diffuse Large B-cell Lymphoma and Follicular Lymphoma [O] . Takako TAKEDA-USUI, Bungo SAITO, Takashi MAEDA, 2009

机译：利妥昔单抗联合TCOP方案在未处理扩散大型B细胞淋巴瘤和滤泡淋巴瘤患者中联合TCOP方案的疗效和不良反应

Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment

著录项

相似文献

相关主题

期刊订阅